We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
58.00 | 3.20% | 1,871.00 | 1,871.00 | 1,873.00 | 1,871.00 | 1,750.00 | 1,750.00 | 170,869 | 12:58:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.35 | 4.1B |
TIDMHIK
RNS Number : 9221Q
Hikma Pharmaceuticals Plc
02 March 2021
Notification and public disclosure of transactions by persons discharging managerial responsibilities
1 Details of the person discharging managerial responsibilities / person closely associated a) Name Douglas Hurt 2 Reason for the notification a) Position/status Non-Executive Director b) Initial notification Initial notification /Amendment 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Hikma Pharmaceuticals PLC b) LEI 549300BNS685UXH4JI75 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of Description: Ordinary shares of 10 pence each the financial (Shares) instrument, type ID Code: GB00B0LCW083 of instrument and identification code b) Nature of the Market purchase of 1,500 Ordinary Shares by transaction Gillian Hurt, spouse of Douglas Hurt c) Price(s) and Price(s): GBP22.65 volume(s) Volume(s): 1,500 d) Aggregated information * Volume 1,500 GBP22.65 GBP33,975 * Price * Total e) Date of the transaction 2 March 2021 f) Place of the London Stock Exchange (XLON) transaction
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
2 March 2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBLGDXXSGDGBD
(END) Dow Jones Newswires
March 02, 2021 11:44 ET (16:44 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions